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This Issue at a GlanceRegenerative medicine, including neuroprotection, gene
therapy, and cell therapy, is a promised land formany ocular degen-
erative diseases such as retinitis pigmentosa and macular degener-
ation. A searchof the literaturewill reveal a largenumberof relevant
reports, but themilk and honey in the promised land is not available
yet in clinical use. The question is when our patients will be able to
receive any beneﬁt from the cutting-edge of new treatments. The
ﬁrst report of human embryonic stem cell (hESC)-derived cells
transplanted into patients with Stargardt’s macular dystrophy or
dry age-related macular degeneration was recently published.1
Over a very short follow-up period of 4 months, vision seemed to
have improved in both patients, and the hESC-derived retinal
pigment epithelium cells showed no signs of hyperproliferation,
tumorigenicity, ectopic tissue formation, or apparent rejection.1 So
far, the outcome has been promising and safedgood news indeed.
In this issue of the Taiwan Journal of Ophthalmology (TJO), Kaplan
and Fernandez de Castro summarize recent advances in the ﬁeld
and the potential they have for the treatment of retinitis pigmen-
tosa and other retinal degenerations. Yin and Lee also report their
marvelous animal studies of cell therapy in Royal College of
Surgeons rats and in minipigs with light induced-degeneration.
Their functional investigations show that transplantation of retinal
stem cells could delay the progress of retinal degeneration in Royal
College of Surgeons rats and light-induced retinal degeneration in
minipigs. These authors also observed that the transplanted retinal2211-5056/$ – see front matter Copyright  2012, The Ophthalmologic Society of Taiwa
doi:10.1016/j.tjo.2012.04.003stem cells had an effect on the processes of dedifferentiation and
redifferentiation of regional Müller cells in transforming into other
retinal neurons such as retinal pigment epithelium cells or photo-
receptors. Readers of TJO may obtain up-to-date information
related to cell therapy in ophthalmology from both review articles.
Inﬂammation plays an important role in age-related macular
degeneration (ARMD). Sheu et al have identiﬁed the
inﬂammation-associated single nucleotide polymorphisms that
modulate ARMD risk. They found a signiﬁcant association between
carriers with polymorphisms of interleukin-4 590 genotypes and
thedevelopmentARMD.ARMD is a complexdisease reﬂecting inter-
actions between genetics and the microenvironment; this report
may contribute to our understanding of the pathogenesis of ARMD.
Lai et al report visual outcomesafterepiretinalmembranesurgery
with or without internal limiting membrane peeling. Although the
visual outcome and macular thickness improved equally in both
groups, the incidence of recurrence was lower in the group who
hadpeeling of the internal limitingmembrane. Recurrence of an epi-
retinal membrane was associated with a poor prognosis.
In a retrospective report of retinopathy of prematurity in infants
with low birthweight, Liu et al concluded that lower gestational
age, lower body weight at birth, a greater degree of respiratory
distress syndrome, prolonged use of oxygen, and a lack of maternal
history of antenatal steroid use are risk factors for the severity of
retinopathy of prematurity.
There is still no consensus about the most effective treatment
for polypoidal choroidal vasculopathy. In a retrospective study in
this issue of TJO, Lee et al report their treatment efﬁcacy of photo-
dynamic therapy with verteporﬁn in patients suffering from poly-
poidal choroidal vasculopathy. After a follow-up lasting more
than 3 years, they found that the visual improvement after treat-
ment of photodynamic therapy with verteporﬁn was temporarily
signiﬁcant at 6 months. Further prospective studies with a control
group and combined therapy may resolve this issue.
In the case report section, both Chen et al’s article on Duane’s
retraction syndrome associated with crocodile tears and hearing
loss, and Lee et al’s paper on chiasmal optic neuritis provide good
information to expand our clinical understanding.
Once again, the efforts of the editorial board of TJO have been
dedicated to providing a high-quality journal for our society
members. The journal’s future success can be assured by your
participation in submitting your papers to TJO.n. Published by Elsevier Taiwan LLC. All rights reserved.
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